What Is the New Vascepa Program?
The "new Vascepa program" refers to the Vascepa Patent Extension and Risk Evaluation and Mitigation Strategy (REMS) program, implemented after Amarin Pharma's 2020 patent settlement with generic manufacturers. It extends Vascepa's (icosapent ethyl) market exclusivity amid ongoing litigation, requiring specific steps for authorized distributors and pharmacies to combat counterfeiting and ensure supply chain integrity [1].
Key Requirements for Distributors and Pharmacies
- Authorized Distributor Designation: Only FDA-registered distributors meeting Vascepa's criteria can purchase and resell the drug. They must sign agreements verifying legitimate sourcing and report suspicious activity [1][2].
- Pharmacy Verification Process: Pharmacies must use the Vascepa Verification Portal to confirm product authenticity before dispensing. This includes scanning lot numbers and checking against Amarin's database [1].
- No Direct Consumer Purchases: Patients cannot buy Vascepa online or from unauthorized sellers; prescriptions must go through verified channels [2].
- Reporting Obligations: Distributors and pharmacies report counterfeit incidents or supply disruptions to Amarin within 24 hours [1].
Who Does This Affect and Why?
Hospitals, clinics, and retail pharmacies must comply to access Vascepa, primarily prescribed for cardiovascular risk reduction in high-triglyceride patients on statins. The program addresses black-market counterfeits identified in 2023 FDA alerts, protecting patients from ineffective or harmful fakes [2][3]. Non-compliance risks supply cutoffs.
How Does It Impact Patients?
Patients face no direct enrollment but may experience delays if pharmacies aren't verified. Prescribers should confirm pharmacy status via Amarin's portal. Copay assistance remains available through the Vascepa Savings Program, unaffected by REMS [1].
Patent and Exclusivity Timeline
Vascepa's core patents expired in 2030, but settlements with Hikma, Dr. Reddy's, and others delay generics until 2027-2039 via the extension program. Check DrugPatentWatch.com for updates on litigation and Paragraph IV challenges [4].
Alternatives if Access Is an Issue
Patients unable to obtain Vascepa can switch to Lovaza (prescription omega-3) or generic icosapent ethyl (if available post-litigation), though efficacy differs for CV outcomes. Consult providers for fish oil supplements, which lack FDA CV indication [3].
Sources:
[1] Amarin Vascepa REMS Website
[2] FDA Drug Safety Communication on Counterfeit Vascepa
[3] FDA Vascepa Label
[4] DrugPatentWatch.com - Vascepa Patents